AYTU BIOPHARMA, INC

For the period ended Dec 31, 2024. Filed Feb 12, 2025.

About this filing

A company's report for each of its first three quarters. The financial statements are not audited. It shows how the business has moved since the last annual report, and what management says changed.

Dec 31, 2024 · Filed Feb 12, 2025

AYTU$1.79-2.2%Stored close · as of Nov 9, 2026

Extracted filing text, with the paragraph anchors used by the comparison.

See the whole filing, with its images and exhibits

Contents

PART I - FINANCIAL INFORMATION Item 1. Financial Statements Unaudited Consolidated Balance Sheets

PART 1 - FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

AYTU BIOPHARMA, INC.

UNAUDITED CONSOLIDATED BALANCE SHEETS

(in thousands, except share data)

	December 31,	June 30,
	2024	2024
ASSETS
Current assets:
Cash and cash equivalents	$20,398	$20,006
Accounts receivable, net	25,403	23,526
Inventories	11,085	12,141
Prepaid expenses and other current assets	6,167	5,097
Current assets of discontinued operations	—	1,121
Total current assets	63,053	61,891
Non-current assets:
Property and equipment, net	516	693
Operating lease right-of-use assets	1,178	829
Intangible assets, net	49,958	52,453
Other non-current assets	1,522	2,185
Non-current assets of discontinued operations	—	44
Total non-current assets	53,174	56,204
Total assets	$116,227	$118,095
LIABILITIES AND STOCKHOLDERS’ EQUITY
Current liabilities:
Accounts payable	$11,699	$10,314
Accrued liabilities	39,372	38,143
Revolving credit facility	4,012	2,395
Current portion of debt	1,857	1,857
Other current liabilities	7,108	8,962
Current liabilities of discontinued operations	—	557
Total current liabilities	64,048	62,228
Non-current liabilities:
Debt, net of current portion	9,983	10,877
Derivative warrant liabilities	6,386	12,745
Other non-current liabilities	5,045	4,529
Total non-current liabilities	21,414	28,151
Commitments and contingencies (note 13)
Stockholders’ equity:
Preferred stock, par value $.0001; 50,000,000 shares authorized; no shares issued or outstanding	—	—
Common stock, par value $.0001; 200,000,000 shares authorized; 6,169,681 and 5,972,638 shares issued and outstanding, respectively	1	1
Additional paid-in capital	348,475	347,688
Accumulated deficit	(317,711)	(319,973)
Total stockholders’ equity	30,765	27,716
Total liabilities and stockholders’ equity	$116,227	$118,095

ContentsView on SEC.gov

The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.